| 摘要 |
Immunonutrition, amodified nutritional formula that involves the addition of glutamine, arginine, omega-3 fatty acids, nucleotides, and other
potential compounds to the diet, has proven its potential for use in immunomodulation and protein metabolism improvement. Its clinical
benefits include shortening hospital stays and lowering surgical infectious complications in upper gastrointestinal surgery. However, the
use of perioperative immunonutrition is rare among colorectal cancer patients undergoing surgical intervention. Colorectal cancer is one
of the most common cancers around the world, but its malnutrition rate is not high in comparison with other cancers (eg, gastric cancer
or esophageal cancer). Furthermore, the surgical modality for the majority of colorectal cancer patients involves minimal invasive surgery
(MIS), which enhances recovery speed. It is an interesting clinical question whether or not perioperative immunonutrition supplementation
for colorectal cancer patients undergoingMIS causes extraclinical impacts. The immunomodulation effect ofCD4+ T cells has been proven
in colorectal patients undergoing elective surgery. In recent years, there have been several prospective randomized studies elucidating
the clinical effects of immunonutrition on colorectal cancer patients undergoing surgery in Western countries. These studies have generally
found that perioperative immunonutrition was associated with a lower rate of surgical infectious complications even in normo-nourished
patients undergoing MIS. The use of perioperative immunonutrition provides clinical benefits according to high-quality studies. However,
most results come from Western countries, and its effect needs to be validated in Asian countries. |
